DURHAM, N.C., Aug. 16, 2022 /PRNewswire/ -- Bio Products Laboratory USA (BPL), a leading manufacturer of plasma-derived protein therapies, today presented initial data from the Hereditary Factor X ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results